JP2022542321A5 - - Google Patents
Info
- Publication number
- JP2022542321A5 JP2022542321A5 JP2022506145A JP2022506145A JP2022542321A5 JP 2022542321 A5 JP2022542321 A5 JP 2022542321A5 JP 2022506145 A JP2022506145 A JP 2022506145A JP 2022506145 A JP2022506145 A JP 2022506145A JP 2022542321 A5 JP2022542321 A5 JP 2022542321A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025105888A JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880044P | 2019-07-29 | 2019-07-29 | |
| US62/880,044 | 2019-07-29 | ||
| US201962892779P | 2019-08-28 | 2019-08-28 | |
| US62/892,779 | 2019-08-28 | ||
| US202062960507P | 2020-01-13 | 2020-01-13 | |
| US62/960,507 | 2020-01-13 | ||
| PCT/US2020/044117 WO2021021963A1 (en) | 2019-07-29 | 2020-07-29 | Nk cell composition and preparations for immunotherapy and methods for their production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105888A Division JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542321A JP2022542321A (ja) | 2022-09-30 |
| JP2022542321A5 true JP2022542321A5 (https=) | 2023-08-07 |
| JPWO2021021963A5 JPWO2021021963A5 (https=) | 2023-08-07 |
Family
ID=74228666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506145A Withdrawn JP2022542321A (ja) | 2019-07-29 | 2020-07-29 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
| JP2025105888A Pending JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105888A Pending JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220275334A1 (https=) |
| EP (1) | EP4004193A4 (https=) |
| JP (2) | JP2022542321A (https=) |
| KR (1) | KR20220038450A (https=) |
| CN (1) | CN114466924A (https=) |
| AU (1) | AU2020321953A1 (https=) |
| CA (1) | CA3145510A1 (https=) |
| IL (1) | IL290080A (https=) |
| MX (1) | MX2022001257A (https=) |
| WO (1) | WO2021021963A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3125503A1 (en) * | 2019-01-18 | 2020-07-23 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP4127188A4 (en) * | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113402620B (zh) * | 2021-07-30 | 2021-12-10 | 中山大学 | 细胞因子联合嵌合抗原受体的融合蛋白及其应用 |
| CN118119636A (zh) * | 2021-08-10 | 2024-05-31 | 盖米达细胞有限公司 | 抗her2 car nk细胞、它们的生产方法及其用途 |
| US20250017964A1 (en) * | 2021-11-15 | 2025-01-16 | City Of Hope | Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy |
| CN114891744B (zh) * | 2022-07-13 | 2022-10-25 | 山东省齐鲁干细胞工程有限公司 | 一种冷冻脐带血nk细胞体外扩增方法 |
| WO2024047368A1 (en) * | 2022-09-02 | 2024-03-07 | Imperial College Innovations Limited | Natural killer cells |
| WO2024113294A1 (zh) * | 2022-12-01 | 2024-06-06 | 血霁生物科技(上海)有限公司 | 一种分化nk细胞的方法、培养基及其应用 |
| CN115927180A (zh) * | 2022-12-01 | 2023-04-07 | 血霁生物科技(上海)有限公司 | 一种分化nk细胞的方法、培养基及其应用 |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| CN116983409B (zh) * | 2023-07-17 | 2025-11-14 | 中国检验检疫科学研究院 | 一种抑制寨卡病毒的方法及其应用 |
| CN118853562B (zh) * | 2024-07-11 | 2025-08-29 | 中国科学院广州生物医药与健康研究院 | 一种靶向cd19的car-nk细胞及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130095079A1 (en) * | 2010-04-09 | 2013-04-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| MY201637A (en) * | 2015-10-15 | 2024-03-06 | Celularity Inc | Natural killer cells and ilc3 cells and uses thereof |
| US20200163993A1 (en) * | 2017-05-09 | 2020-05-28 | Saint Louis University | Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes |
-
2020
- 2020-07-29 CA CA3145510A patent/CA3145510A1/en active Pending
- 2020-07-29 JP JP2022506145A patent/JP2022542321A/ja not_active Withdrawn
- 2020-07-29 EP EP20848443.6A patent/EP4004193A4/en active Pending
- 2020-07-29 KR KR1020227006075A patent/KR20220038450A/ko active Pending
- 2020-07-29 AU AU2020321953A patent/AU2020321953A1/en active Pending
- 2020-07-29 CN CN202080067440.2A patent/CN114466924A/zh active Pending
- 2020-07-29 US US17/631,035 patent/US20220275334A1/en active Pending
- 2020-07-29 MX MX2022001257A patent/MX2022001257A/es unknown
- 2020-07-29 WO PCT/US2020/044117 patent/WO2021021963A1/en not_active Ceased
-
2022
- 2022-01-24 IL IL290080A patent/IL290080A/en unknown
-
2025
- 2025-06-23 JP JP2025105888A patent/JP2025156345A/ja active Pending